The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure

Natalia Stella-Ascariz; José Ramón Arribas; Roger Paredes; Jonathan Z Li

doi:10.1093/infdis/jix430

The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure

J Infect Dis. 2017 Dec 1;216(suppl_9):S847-S850. doi: 10.1093/infdis/jix430.

Authors

Natalia Stella-Ascariz¹, José Ramón Arribas², Roger Paredes³, Jonathan Z Li⁴

Affiliations

¹ Microbiology Service, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ.
² HIV Unit, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ.
³ HIV Unit and irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona and Universitat de Vic-UCC, Spain.
⁴ Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School.

Abstract

Human immunodeficiency virus type 1 (HIV-1) drug resistance genotyping is recommended to help in the selection of antiretroviral therapy and to prevent virologic failure. There are several ultrasensitive assays able to detect HIV-1 drug-resistance minority variants (DRMVs) not detectable by standard population sequencing-based HIV genotyping assays. Presence of these DRMVs has been shown to be clinically relevant, but its impact does not appear to be uniform across drug classes. In this review, we summarize key evidence for the clinical impact of DRMVs across drug classes for both antiretroviral treatment-naive and antiretroviral treatment-experienced patients, and highlight areas where more supporting evidence is needed.

Keywords: HIV-1 drug resistance; drug resistant minority variants; treatment failure.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / therapeutic use*
Drug Resistance, Viral / genetics
HIV Infections / drug therapy*
HIV Infections / virology
HIV-1 / drug effects
HIV-1 / genetics*
Humans
Treatment Failure

Substances

Anti-HIV Agents